Search results :

Balsalazide

More information: STITCH, PubChem and possibly Wikipedia

ATC Code: A07EC04

Side effects

Options: Show MedDRA Preferred Terms

Side effect Data for drug Placebo Labels
1 2 3 4 5 6 7
Headache 8% - 15.2% x x x x x x x
Abdominal pain upper 9.09% - 17.1% x x x x
Abdominal pain 6% - 12.1% 2.86% x x x x x x x
Colitis ulcerative 5.71% - 6.06% x x x x
Nasopharyngitis 2.86% - 9.09% x x x x x
Body temperature increased 0% - 11.4% 0% x x x x x x x
Diarrhoea 3.7% - 11.4% 0% - 2.86% x x x x x x x
Nausea 0% - 8.57% x x x x x x
Haematochezia 0% - 8.57% x x x x
Influenza 3.03% - 5.71% x x x x
Arthralgia 2.4% - 4% 0% x x x x x x x
Respiratory tract infection 4% x x x x x x
Vomiting 3.03% - 17.1% x x x x x x x
Anaemia 3.7% 0% x x x x x x x
Dysmenorrhoea 0% - 6.06% x x x x
Stomatitis 0% - 5.71% x x x x
Pharyngolaryngeal pain 0% - 6.06% 0% x x x x x
Fatigue 2% - 6.06% 0% x x x x x x x
Musculoskeletal pain 2.4% 0% x
Rhinitis 2% - 2.32% 0% x x x x x x
Insomnia 2% - 2.4% 0% x x x x x x x
Cough 0% - 5.71% 0% x x x x x x
Dyspepsia 1.93% - 2% 0% x x x x x x
Flatulence 1.93% - 2% 0% x x x x x x x
Anorexia 1.54% - 2% 0% x x x x x x
Pharyngitis 1.54% - 2% 0% x x x x x x
Constipation 1% - 1.16% 0% x x x x x x x
Cramp muscle 1% - 1.16% 0% x x x x x x
Urinary tract infection 1% - 3.7% 0% x x x x x x x
Dry mouth 1% - 1.16% 0% x x x x x x x
Myalgia 1% - 1.16% 0% x x x x x x x
Alopecia postmarketing x x x x x x x
Eosinophilia postmarketing x x x x
Jaundice postmarketing x x x x x x x
Jaundice cholestatic postmarketing x x x x x x x
Myocarditis postmarketing x x x x
Nephritis interstitial postmarketing x x x x
Pancreatitis postmarketing x x x x
Pericarditis postmarketing x x x x
Pleural effusion postmarketing x x x x
Pneumonia postmarketing x x x x
Pruritus postmarketing x x x x
Renal failure postmarketing x x x x
Vasculitis postmarketing x x x x
Hepatic failure postmarketing x x x x x x x
Hepatic function abnormal postmarketing x
Hepatocellular injury postmarketing x x x x x x x
Hepatic necrosis postmarketing x x x x x x x
Hepatotoxicity postmarketing x x x x x x
Hepatic enzyme increased postmarketing x
Hepatobiliary disease postmarketing x
Blood bilirubin increased postmarketing x
Alveolitis postmarketing x x x x
Raised liver function tests postmarketing x x x x x x
Back pain x
Infection x
Connective tissue disorder x
Dizziness x
Dyspnoea x
Erythema nodosum x
Rash x
Gastroenteritis x
Gastrooesophageal reflux disease x
Gastrointestinal disorder x
Lethargy x
Mediastinal disorder x
Nervous system disorder x
Pain x
Swelling x
Tachycardia x
Upper respiratory tract infection x
Aspartate aminotransferase increased x
Malaise x
Rectal haemorrhage x x x x x x
Faeces hard x
Defaecation urgency x
Blood pressure increased x
Face oedema x
Infestation NOS x

Indications

Information about indications was extracted from the indications and usage sections of the labels.

BALSALAZIDE DISODIUM / COLAZAL

Side effects:39
Source:FDA

balsalazide

Side effects:39
Source:FDA Structured Product Label

BALSALAZIDE DISODIUM / COLAZAL

Side effects:39
Source:FDA

BALSALAZIDE

Side effects:42
Source:FDA Structured Product Label

BALSALAZIDE

Side effects:42
Source:FDA Structured Product Label

BALSALAZIDE

Side effects:50
Source:FDA Structured Product Label

BALSALAZIDE

Side effects:62
Source:FDA Structured Product Label

Color scheme:

standard – alternative

    100%
    75%
    50%
    10%
    frequent (1% to 100%)
    infrequent (0.1% to 1%)
    rare (<0.1%)
    postmarketing
    0%
    no frequency information
    not found on label